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ABSTRACT 
 
BACKGROUND: This was a national English observational cohort study to estimate the 
effectiveness of inpatient withdrawal (IW) and residential rehabilitation (RR) interventions 
for alcohol use disorder (AUD) using administrative data. 
METHODS: All adults commencing IW and/or RR intervention for AUD between April 1 
2014 and March 31 2015 reported to the National Drug Treatment Monitoring System 
(n=3,812). The primary outcome was successful completion of treatment within 12 months of 
commencement, with no re-presentation (SCNR) in the subsequent six months, analysed by 
multi-level, mixed effects, multivariable logistic regression. 
RESULTS: The majority (70%, n=2,682) received IW in their index treatment journey; one-
quarter (24%, n=915) received RR; 6% (n=215) received both. Of treatment leavers, 59% 
achieved the SCNR outcome (IW: 57%; RR: 64%; IW/RR: 57%). Positive outcome for IW 
was associated with older age, being employed, and receiving community-based treatment 
prior to and subsequent to IW. Patients with housing problems were less likely to achieving 
the outcome. Positive outcome for RR was associated with paid employment, self/family/peer 
referral, longer duration of RR treatment, and community-based treatment following 
discharge. Community-based treatment prior to entering RR, and receiving IW during the 
same treatment journey as RR, were associated with lower likelihood of SCNR. 
CONCLUSIONS: In this first national effectiveness study of AUD in the English public 
treatment system for alcohol-use disorders, 59% of patients successfully completed treatment 
within 12 months and did not represent for more treatment within six months. Longer 
duration of treatment and provision of structured continuing care is associated with better 
treatment outcomes.  
 
KEYWORDS: alcohol; inpatient; residential; treatment; alcohol use disorder 
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1. Introduction 
Alcohol use is a leading risk factor for morbidity and mortality (World Health Organisation, 
2014). An estimated 3.6% of the global population aged 15-64 years meet criteria for alcohol 
use disorder each year (AUD; American Psychiatric Association, 2013), with relatively 
higher rates estimated for Europe (5.5%; Rehm et al., 2009). Negative health, social and 
economic consequences are higher among the population with AUD (Hasin, Stinson, Ogburn, 
& Grant, 2007; Odlaug et al., 2016). In Europe, it is estimated that AUDs are responsible for 
60% of alcohol-related mortality (Rehm, Shield, Gmel, Rehm, & Frick, 2013). There are 
concerns that only a minority of people with AUD access treatment services (United Nations, 
2015). For example, in England just 6% of those with AUD in England receive treatment 
(National Institute for Health and Care Excellence, 2011; UK Home Office, 2012).  
 
The goal of AUD treatment is to help patients quit drinking or prevent harmful consumption, 
thereby reducing the health, social and economic harms (Haber, Lintzeris, Proude, & 
Lopatko, 2009; Rahhali et al., 2015). In the English public healthcare system, structured 
AUD treatment is mainly delivered by National Health Service or third-sector providers in 
the outpatient/community setting, offering psychosocial interventions (including 
motivational, cognitive behavioural, family/social network modalities and facilitation of 
access to 12-step groups) and pharmacotherapies (including acamprosate and naltrexone for 
approximately 6 months). 
 
This is complemented by a relatively small number of inpatient withdrawal (IW) and 
residential rehabilitation (RR) services. Patients are treated in the community or 
inpatient/residential setting based on a clinical assessment of problem severity and 
complexity; patient preference; and service availability (National Institute for Health and 
Care Excellence, 2011). There is some provision of detoxification management in the 
community over 7-10 days typically using benzodiazepines (National Institute for Health and 
Care Excellence, 2011).  
 
IW or RR are usually indicated for people with greater AUD severity (e.g. those drinking 
more than 30 standard drinks per typical drinking day), or instances of complexity due to 
unstable housing; comorbid psychiatric/physical conditions; or a history of seizures. IW is 
usually 5-7 nights in a controlled hospital environment with pharmacological interventions 
for medical management of withdrawal (National Institute for Health and Care Excellence, 
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2011). RR is usually a 6-12 weeks stay in a structured, residential facility which provides a 
phased, structured programme of psychosocial interventions. Detoxification support may be 
provided as needed. RR programmes usually follow an underlying therapeutic philosophy, 
including 12-step; therapeutic community; faith-based practice; cognitive behavioural therapy 
and social learning; personal and skills development; or an eclectic/integrated approach 
(Moos, Moos, & Andrassy, 1999).  
 
Routine delivery of AUD treatment interventions is remarkably under-researched. Our group 
has previous reported reductions in offending associated with AUD treatment (Willey et al., 
2016), but there have been no national outcome studies. Addressing this gap is important 
because treatment outcomes in the clinic cannot be assumed to be the same as randomised 
controlled trials. AUD intervention trials are often designed to answer questions of efficacy; 
with participants selected on restricted characteristics (Witkiewitz, Finney, Harris, Kivlahan, 
& Kranzler, 2015); using very detailed research assessment procedures (Epstein et al., 2005); 
and implemented with complex intervention exposures that are not routinely available in the 
healthcare system (Allen et al., 1997).  
 
The National Drug Treatment Monitoring System (NDTMS; Public Health England, 2015b) 
evaluates all public AUD treatment services in England (NDTMS; Public Health England, 
2015b). NDTMS has been in operation since 2005/06 and had an initial focus on services 
providing structured treatment and care for people with drug use disorders. All operational 
public alcohol and drug treatment services who deliver treatment interventions now report to 
the system, and ~98% of patients consent to the use of their administrative and clinical data 
for local treatment system needs assessment and national research (Marsden et al., 2009; 
Marsden et al., 2012; White et al., 2015; Willey et al., 2016) 
 
In 2008/09, NDTMS was enhanced to monitor outcomes from all public treatment services 
for AUD. Elsewhere, we report on the effectiveness of community-based AUD interventions 
(Peacock et al., under review). In this report, we estimate the clinical effectiveness of IW and 
RR interventions for AUD in the English public healthcare system. 
 
2. Materials and Methods 
2.1 Design 
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This was an observational, follow-up study of all individuals accessing publicly funded, IW 
and/or RR treatment for AUD in England. The study included all 152 upper-tier local 
authorities within England, and all specialist AUD services. The study is reported according 
to the STROBE and RECORD guidelines for cohort research (Benchimol et al., 2015).  
 
2.2 Patient and treatment information 
NDTMS records were accessed on patient-demographic, behavioural, clinical and treatment 
outcome variables for each episode of treatment, including the dates of starting and finishing 
specific treatment interventions and the treatment exit date (Public Health England, 2015a, 
2015b). 
 
Reflecting national reporting standards (Public Health England, 2015b), individual treatment 
episodes were concatenated into ‘treatment journeys’, whereby multiple episodes 
(community-based or residential program) are subsumed under a single journey. AUD 
intervention episodes were allocated to the same journey if fewer than 21 days elapsed 
between the date of ending one treatment modality and the date of starting a subsequent one. 
In this way, a treatment journey for a patient could comprise a single intervention episode; 
concurrent episodes provided by more than one agency; or a continuing care package of 
consecutive episodes provided by one or more service providers. 
 
2.3 Study cohort 
The study population was adults (aged ≥18 years) who commenced IW and/or RR treatment 
for primary AUD between 1 April 2014 and 31 March 2015 (N=3,861). Patients were not 
included in the study cohort if they: (1) reported problematic use of other psychoactive 
substances at assessment; (2) had missing information on drinks per drinking day (DDD) at 
both triage and treatment admission; or (3) had missing information on clinical status at 
discharge were not considered for inclusion.  
 
Analyses were based on the patient’s first treatment journey during the period (hereafter 
‘index journey’). The observation period commenced from the date of starting IW or RR and 
ended: (1) six months after the date of discharge from the index journey, if discharge 
occurred within 12 months of starting IW or RR, or (2) 12 months after starting IW or RR if 
the patient was not yet discharged (the latter group was excluded from analysis of the primary 
outcome). Periods in community-based treatment subsequent but not prior to IW or RR, 
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contributed to the observation time, with discharge date adjusted accordingly. If the index 
journey involved progression from IW or RR, or vice versa, it was categorised as involving 
both. 
 
2.4 Outcome measure 
The study outcome measure is the English national outcome standard, defined as the 
proportion of the cohort that successful completed treatment within 12 months of 
commencement with no representation within six months (SCNR; Public Health England, 
2015b).  
 
The proportion of patients treated who complete treatment successfully has been used before 
in the AUD treatment literature (Alterman, Langenbucher, & Morrison, 2001). This outcome 
may be associated with improvements in personal and social functioning (Finigan, 1996), but 
it does not identify sustained benefit. This is important given the relapsing nature of AUD. In 
the present context, re-presentation for further AUD treatment within six months of discharge 
is taken to be an indicator of remission. 
 
Treatment journeys were categorised according to clinical assessment of the patient’s 
discharge status, as: (1) successfully completed treatment within 12 months; (2) retained in 
the same treatment journey at 12 months from entry; or (3) withdrawn from treatment journey 
within 12 months of entry (unsuccessful transfer between agencies; treatment terminated due 
to incarceration; patient dropped out treatment died during treatment). Successful treatment 
was defined as the patient being discharged having: completed their care plan, with no AUD 
(and either abstinent or no heavy drinking), and no re-presentation to any service for further 
AUD treatment within six months of concluding their treatment journey (Eastwood, Strang, 
& Marsden, 2017; Peacock et al., under review; Public Health England, 2016).  
 
2.5 Covariates 
Following our general evaluation approach (Willey et al., 2016), the analysis included patient 
socio-demographics; indicators of clinical severity/case complexity; and summary measures 
of treatment journey exposure. Possible covariates were identified from reviews of predictors 
of treatment outcome (Adamson et al., 2009; Brorson, Arnevik, Rand-Hendriksen, & 
Duckert, 2013). Patient-level measures were recorded at triage assessment at the first 
admission to the index journey. The following covariates were included: 
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2.5.1 Socio-demographics. Analyses were adjusted for: age (years), gender, ethnic origin, 
housing problems (homeless, in short-term hostel provision, or at risk of eviction in the past 
28 days); and employment (whether in paid work in past 28 days). Analyses were also 
adjusted for an indicator of social deprivation, imputed by assigning patients to their electoral 
ward of residence, based on the partial postal code recorded by NDTMS, categorised 
according to the Department for Communities and Local Government ward-level Indices of 
Multiple Deprivation (IMD; Department for Communities and Local Government, 2015). If 
the partial postcode could be located in more than one electoral ward the median IMD score 
was assigned. The IMD score for the first treatment service address within the treatment 
journey was assigned if partial postcode was missing. Following UK local government 
reporting convention (Public Health England, 2015a), IMD scores were grouped by quintile.  
 
2.5.2 Clinical characteristics. Analyses were adjusted based on patients’ self-report of the 
number of days on which they consumed alcohol; and the number of standard DDD in the 
previous 28 days. These were recorded via the Treatment Outcomes Profile (TOP; Marsden 
et al., 2008). TOP is the national clinical outcome measure in NDTMS, administered as a 
face-to-face structured clinical interview, with timeline follow-back technique to maximise 
recall accuracy (Sobell, Sobell, Leo, & Cancilla, 1988). Reflecting National Institute for 
Health and Care Excellence (2011) guidelines, DDD were categorised as: abstinent (i.e. zero 
drinks in the past 28 days); low to high (1 to 15 DDD); high to extreme (16 to 30 DDD); and 
extreme ( 31 DDD). We also adjusted for source of treatment referral (health service; 
self/friend/family; criminal justice system), and whether the patient had previously received 
AUD treatment as recorded in NDTMS (i.e., from 2006 onwards). 
 
2.5.3 Treatment exposure. Analyses were adjusted based on receipt within the index 
treatment journey involving: (1) community-based treatment that started prior to the RR or 
IW component; (2) community-based treatment that ended following cessation of RR /IW; 
and (3) recovery support (treatment agency provision or referral for: facilitated access to 
mutual aid; peer support involvement, family, parenting, support groups; housing, 
employment, education and training support; and complementary therapies). The total 
duration of treatment exposure, IW exposure, and RR exposure was recorded in days (IW) or 
weeks (RR) from the start of the index journey to discharge, right censored at 365 days and 
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computed using the triage and discharge date for the specific intervention. Pharmacological 
intervention provided during residential rehabilitation was indicator coded (0,1).  
 
2.6 Statistical analysis  
In this national treatment population study, with a hierarchical design and participants 
grouped in treatment services, our statistical power concerns reflected control of clustering 
effects and minimising bias of model coefficients. We note that multi-level simulation studies 
have concluded that power is increased by adding groups rather than the number of cases per 
group. In the event, our sample well exceeded the minimum recommended for multi-level 
designs (e.g. 50 groups for random effects models; Maas & Hox, 2005).  
 
Stata (Stata version 13.1; Stata Corporation, College Station, TX, USA) was used for 
analyses. All estimates were computed with associated 95% confidence intervals (CI). A 
multi-level approach to analysis was chosen given that individuals were nested within 
agencies. Multinomial logistic regression (command: mlogit) with robust standard errors was 
used to adjust for clustering of participants within treatment services and to identify 
correlates of IW and RR (i.e., ‘IW group’, ‘RR group’, ‘IW and RR group’). The analysis of 
SCNR excluded those individuals who did not leave treatment within 12 months of initiation. 
 
Missing data for employment, housing status, days of alcohol use and DDD from standard 
assessment procedures were replaced with data from the initial TOP assessment interview 
where available. Despite this, missing values were recorded for covariates ethnicity (n=82), 
paid employment (n=159), unstable housing (n=46 cases), and referral source (n=19). With 
evidence that data loss was not missing-at-random (Little & Little, 2002), we used a multiple 
imputation via chained equations procedure (command: mi: impute chained). An all-case 
multivariate logistic model was run to check on potential bias and loss of precision (Sterne et 
al., 2009). To achieve a relative efficiency above 98% (Rubin, 1987) and to ensure that 
reduction in power was less than 1% (Graham, Olchowski, & Gilreath, 2007), 20 datasets of 
probabilistic values were created, each analysed separately, and then combined using Rubin’s 
rules. 
 
Models were run separately for participants of each treatment setting (i.e., IW versus RR) for 
analysis of the SCNR outcome (command: meqrlogit with 7 integration points), with patient-
level covariates were included as fixed effects. Simulation studies suggest a minimum of 10 
9 
 
or more events per covariate in logistic regression analyses; this criteria was satisfied in the 
current analyses (Peduzzi, Concato, Kemper, Holford, & Feinstein, 1996). For the purpose of 
these analyses, those participants who had received both IW and RR were included in 
analyses for the RR model, and a covariate identifying receipt of IW was included in the 
model.  Models based on imputation are reported in-text; complete-case analyses are 
available in supplementary materials.  
 
3. Results 
3.1 Socio-demographic and clinical characteristics  
The majority of patients were male (65%) and the median age was 46 years (Table 1). Half 
(53%) had a history of structured AUD treatment prior to their index journey. Median 
drinking days at triage was 28 (i.e., daily in the past month), and the majority were classified 
as ‘High to Extreme’ (49%) or ‘Extreme’ (30%) based on DDD.  
 
3.2 Treatment exposure and status 
Most patients (70%, n=2,682) received IW treatment (‘IW group’); one-quarter (24%, n=915) 
received RR treatment (‘RR group’); and 6% (n=215) received both (‘Combined group’). 
Compared to the ‘IW group’ (referent), patients in the ‘RR’ and ‘Combined’ groups were 
slightly younger and less likely to be male. The ‘RR group’ were more likely to report: 
housing problems; self, family, or peer referral to treatment; and to report abstinence at triage 
(Table 2). 
 
The cohort accessed 171 specialist IW and RR treatment services (median of 7 clients per 
agency, IQR 2-23). Median duration of treatment exposure for the ‘Combined group’ (25 
weeks; IQR 13-41) was greater than that of the ‘IW group’ (6 weeks, IQR 2-20), with the ‘RR 
group’ reporting a median of 13 weeks (IQR 6-24) in treatment.  
 
Half (53%) of the cohort received structured community-based treatment prior to the earliest 
IW or RR admission within their index treatment journey (Table 1). The relative risk of prior 
community-based treatment was lower for the ‘RR group’ relative to the ‘IW group’. A 
similar proportion (52%) received community-based treatment subsequent to IW or RR 
cessation, although delivery was less likely for the ‘RR’ and ‘Combined’ groups. Two-thirds 
(66%) received recovery support within their treatment journey.  
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Three-fifths of the sample (60%) successfully completed their index treatment journey within 
12 months of admission to IW or RR; nearly one-fifth (17%) were unsuccessfully referred to 
an agency, one-sixth (15%) had an unplanned discharge, and less than one-tenth (7%) were 
still in their index treatment journey at the end of observation (Table 3).  
 
Relative to the ‘IW group’, the ‘RR group’ were less likely to be recorded as having an 
unsuccessful transfer between agencies (RR 0.51, 95%CI 0.27, 0.96, p=0.037). Further, the 
‘RR group’ had a lower risk ratio (RR 0.60, 95%CI 0.36, 0.98, p=0.041), and the ‘Combined 
group’ had a higher risk ratio (RR 1.78, 95%CI 1.07, 2.96, p=0.028), of being retained in the 
index treatment journey 12 months post-admission.  
 
3.3 SCNR outcome 
Three-fifths (59%) of those who left treatment within 12 months of commencement (i.e., 
excluding those still in treatment) achieved SCNR (IW: 57%; RR: 64%; Combined: 57%).  
 
A multi-level, mixed effects, multivariable logistic model for the ‘IW group’ showed that 
being older, engaged in paid employment, and receiving community-based treatment prior 
and subsequent to IW were associated with greater likelihood of the SCNR outcome (Table 
4). Having a housing problem was a negative predictor of the SCNR outcome. Notably, the 
odds of the SCNR outcome were 59% higher for those who received community-based 
treatment prior to IW, and 47% higher for those who received community-based treatment 
subsequent to IW. No such association was evident for provision of recovery support 
throughout the treatment journey.  
 
For the RR analysis, a multi-level, mixed effects, multivariable logistic model (i.e., ‘RR 
group’ and ‘Combined group’) showed that being engaged in paid employment, 
self/family/peer referral to treatment, a longer duration of RR treatment exposure, and receipt 
of community-based treatment subsequent to RR were associated with greater likelihood of 
achieving the SCNR outcome. Receiving community-based treatment prior to RR, and IW in 
the same treatment journey as RR, were associated with a lower likelihood of this outcome 
(Table 4). Notably, the odds of SCNR were 69% higher for those who received structured 
outpatient intervention after RR; no such association was evident for provision of recovery 
support.  
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3.4 Sensitivity analyses 
Models for IW and RR groups were repeated using complete-case data (Table S1) and were  
comparable. We calculated the E-value for a common outcome (where the outcome >15%). 
The E-value is an estimate of the minimum strength of association that an unmeasured 
confounder would need to account for a treatment-outcome association, conditional on the 
included covariates (VanderWeele & Ding, 2017).  
 
For the IW model, the magnitude of the observed AOR for prior structured community-based 
treatment (1.59) and for subsequent structured community-based treatment (1.47) was relatively 
protected from influence of unmeasured confounding. The E-value indicated that these treatment-
outcome associations could be explained away by an unmeasured confounder, but only one that that 
was associated with both the treatment and the outcome with a risk ratio of 1.83 and 1.72, 
respectively. Weaker unmeasured confounding could not do so, although the confidence intervals 
could be moved towards the null with smaller risk ratios (1.38 and 1.29, respectively). For the RR 
model, the observed AORs of 0.67 for prior community-based treatment and 1.69 for subsequent 
community-based treatment could be explained away by E-values of 1.74 and 1.92, respectively and 
with relative modest impact of the confidence intervals towards the null (1.08 and 1.28, respectively).  
 
4. Discussion 
The aim of this study was to estimate the clinical effectiveness of publicly-funded IW and RR 
treatment for AUD in England. In this national cohort, categorisation of patients who entered 
a form of accommodation-based treatment revealed that the majority received treatment in an 
IW setting; less than one-third entered a RR facility. IW is recommended where individuals 
are at risk of alcohol withdrawal seizures or delirium tremens, and thus require medically-
assisted alcohol withdrawal and 24 hour assessment and monitoring (National Institute for 
Health and Care Excellence, 2011). RR is typically recommended where the individual may 
not have stable housing and/or may require intensive treatment longer-term (National 
Institute for Health and Care Excellence, 2011). Whilst pharmacological intervention may be 
offered in some RR facilities, abstinence on treatment commencement can be a requirement. 
Indeed, the current study showed that those who received RR were more likely to be 
homeless or at housing risk, had a longer duration of treatment exposure, and were more 
likely to report abstinence at triage, relative to those who received IW.  
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Notably, half the sample had received outpatient treatment prior to IW/RR, with greater 
prevalence amongst IW patients. Outpatient-based community-assisted withdrawal programs 
with psychosocial intervention and a medication regime where necessary are recommended 
as the first-line response to AUD (National Institute for Health and Care Excellence, 2011). 
Half the sample received structured outpatient treatment after discharge from 
accommodation-based treatment, and two-thirds received some form of recovery support, 
showing general support for recommendations regarding engagement in continuing care in 
outpatient settings (National Institute for Health and Care Excellence, 2011).   
 
Over half of those who left treatment (planned or unplanned) achieved SCNR, with a higher 
rate amongst those who received RR versus IW. The present study is not able to shed light on 
the relative efficacy of treatment here given that participants were not randomly allocated to 
settings. However, IW is often considered the first step in the treatment journey, focused 
purely on withdrawal, whilst RR is often focused on maintenance of abstinence (National 
Institute for Health and Care Excellence, 2011). Further, IW is typically a week or so in 
duration, and RR several months. Longer duration of treatment, as opposed to treatment 
intensity, is associated with better short and long-term outcomes, including abstinence, 
severity of dependence and broader psychosocial wellbeing (Moos & Moos, 2003). 
  
The analysis of correlates of SCNR for those who received IW and RR revealed that longer 
duration of exposure to IW or RR predicted greater likelihood of SCNR after covariate 
control. Previous AUD treatment exposure was associated with lower odds of SCNR, 
aligning with current understanding of AUD as a chronic, remitting condition (Grahn, 
Chassler, & Lundgren, 2014). Receipt of community-based treatment following discharge 
from IW or RR, what we would term here ‘continuing care’, was associated with greater odds 
of SCNR across both subsamples. Continuing care has been defined as treatment which 
follows a period of more intensive care, typically IW/RR or intensive outpatient care, 
intended to maintain progress and provide support for continued engagement in other 
recovery activities (McKay, 2009). Whilst there is considerable variability in patient 
response, there is evidence to support a positive effect of continuing care in enhancing 
positive short- and long-term treatment outcomes (McKay, 2002, 2009). Indeed, several 
studies have shown increased rates of abstinence over time with provision of structured 
outpatient psychosocial treatment following RR and IW for problematic alcohol and other 
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drug use (Gossop et al., 2003; Gossop, Stewart, & Marsden, 2008; Kim et al., 2012; 
Ouimette, Moos, & Finney, 1998).  
 
We did not observe a significant association between provision of recovery support and 
SCNR for IW or RR subsamples. Recovery support can be delivered and recorded outside 
structured treatment, and comprises activities targeted at relapse prevention (e.g., periodic 
contact between provider and client regarding recovery progress) and supports for broader 
functioning (e.g., employment, housing, parenting, family). It should be noted that non-
structured recovery support is not captured within NDTMS, nor is services offered outside of 
reporting agencies, so rates of engagement in recovery support may be under-ascertained.   
 
5.1 Strengths and limitations 
Past research exploring outcomes following AUD treatment within IW and RR settings is 
typically restricted to prospective cohort studies, focusing on achievement of abstinence, as 
well as retention and successful completion of treatment (Gossop et al., 2003). To the best of 
our knowledge, this is the first study of IW and RR treatment outcomes, as conceptualised, 
using a national monitoring system.  
 
We acknowledge several study limitations. Firstly, the sample was restricted to those who 
reported only problematic alcohol use. Whilst existing research indicates high comorbidity 
between AUD and other substance disorders (Stinson et al., 2005), annual 2014/15 NDTMS 
data (Public Health England, 2015a) indicated that alcohol only patients formed 30% of the 
total treatment population, and patients with comorbid alcohol and non-opiate problematic 
use only 10%. Second, NDTMS lacks research measures of self-efficacy, personality traits 
and specific co-existing mental health conditions, so there is relatively limited opportunity for 
confounder control and evaluation of outcome mediation, and these are recognised as 
potential unmeasured confounders (Adamson et al., 2009). However, we included an analysis 
of the strength of unmeasured confounding (using the E-value) and found that this was not 
likely to represent a threat to the adjusted models; although the assessment of unmeasured 
confounding for the RR model did point to some imprecision in the confidence intervals for 
the intervention-outcome associated identified.  
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Third, we were not able to link treatment records to national deaths registry or the national 
prisons system, meaning that we could not censor data for barriers to treatment re-
presentation, and privately-funded treatment may not be captured in NDTMS. Given that 
only 1.2% of the sample ceased treatment within 12 months of admission due to mortality, 
we do not anticipate that the rate of SCNR would decrease substantially accounting for these 
factors.   
 
Fourth, SCNR outcome is a proxy for remission. It does not include people who have 
relapsed but not, for whatever reason, not re-presented to treatment. This sub-group are 
detectable by research studies with research follow-up, but are not detectable by data 
registries such as NDTMS. Fifth, whilst our definition of SCNR matched national reporting 
standards (Public Health England, 2015b), further research using longer period to identify 
relapse (≥12 months) could evaluate benefit in the longer-term. Finally, it should be 
emphasised that this study does not comprise a comparison of treatment outcomes for IW 
versus RR given that patients were not randomised to setting. 
 
5.2 Conclusion 
In this first national effectiveness study of AUD in the English public treatment system for 
alcohol-use disorders, 59% of patients successfully completed treatment within 12 months 
and did not represent for more treatment within six months. Greater likelihood of SCNR with 
longer treatment exposure aligns with current literature suggesting that the duration of 
treatment may be critical in determining outcomes. Further, provision of continuing care in 
the form of structured outpatient intervention was associated with greater likelihood, and 
previous history of AUD treatment was associated with lower likelihood, of successful 
completion without re-presentation. Taken together, these findings reinforce current 
conception of AUD as a chronic condition, whereby continued provision of support over time 
may delay the time until relapse.  
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Table 1 
Socio-demographic, clinical/treatment characteristics of the cohort (n=3,812) 
Characteristic 
IW  
(n=2,682) 
RR  
(n=915) 
Combined  
(IW + RR; n=215) 
Total 
(n=3,812) 
Socio-demographic a     
No. (%) male  1792 (66.8) 569 (62.2) 129 (60.0) 2490 (65.3) 
Age (M, IQR) 47 (40, 54) 45 (37, 51) 45 (37, 52) 46 (39, 53) 
No. (%) Black or minority ethnic group 309 (11.7) 86 (9.9) 22 (10.4) 417 (11.2) 
No. (%) deprivation quintile      
   1 (least deprived) 508 (18.9) 212 (23.2) 33 (15.3) 753 (19.8) 
   2 442 (16.5) 219 (23.9) 47 (21.9) 708 (18.6) 
   3 494 (18.4) 143 (15.6) 54 (25.1) 691 (18.1) 
   4  550 (20.5) 168 (18.4) 49 (22.8) 767 (20.1) 
   5 (most deprived) 688 (25.7) 173 (18.9) 32 (14.9) 893 (23.4) 
No. (%) with housing problems  358 (13.5) 196 (21.8) 39 (18.2) 593 (15.7) 
No. (%) in paid employment  438 (17.1) 160 (18.2) 37 (17.5) 635 (17.4) 
Clinical a     
Days alcohol use (M, IQR)  28 (28, 28) 28 (14, 28) 28 (28, 28) 28 (28, 28) 
No. (%) DDD group: b     
Abstinent  113 (4.2) 122 (13.3) 11 (5.1) 246 (6.5) 
Low-High  408 (15.2) 110 (12.0) 28 (13.0) 546 (14.3) 
High-Extreme  1340 (50.0) 438 (47.9) 103 (47.9) 1881 (49.3) 
Extreme 821 (30.6) 245 (26.8) 73 (34.0) 1139 (29.9) 
No. (%) previous treatment for AUD  1458 (54.4) 442 (48.3) 129 (60.0) 2029 (53.2) 
No. (%) referral route:     
Health service 897 (33.5) 409 (45.4) 81 (37.7) 1387 (36.6) 
Self/family member/friend 33 (1.2) 12 (1.3) 5 (2.3) 50 (1.3) 
Criminal justice 1748 (8.6) 479 (53.2) 129 (60.0) 2356 (62.1) 
Treatment exposure      
Total weeks in treatment (M, IQR) 6 (2-20) 13 (6-24) 25 (13-41) 9 (2-23) 
No. (%) prior structured community-based treatment  1526 (56.9) 359 (39.2) 144 (67.0) 2029 (53.2) 
Total days community-based treatment (M, IQR) 62 (35-104) 84 (50-133) 83 (49-132) 67 (38-111) 
No. (%) subsequent structured community-based treatment 1627 (60.7) 252 (27.5) 84 (39.1) 1963 (51.5) 
No. (%) recovery support 1,952 (69.6) 453 (49.1) 184 (87.6) 2,589 (65.7) 
IW, inpatient withdrawal; RR, residential rehabilitation; IW + RR, inpatient withdrawal and residential rehabilitation; M, median; IQR, inter-quartile range; DDD, drinks per 
drinking day; AUD, alcohol use disorder. 
a Recorded at triage assessment with reference to the preceding 28 days as appropriate; b Recoded at treatment commencement with reference to the preceding 28 days were 
appropriate.  
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Table 2 
Likelihood of IW and RR group classification: by socio-demographic and clinical/treatment characteristics 
(n=3,812) 
 
Covariate 
RR  
(n=915) 
Combined  
(IW + RR; n=215) 
Socio-demographic a   
Male  0.82 (0.68, 0.99), p=0.037 0.74 (0.57, 0.97), p=0.031 
Age 0.98 (0.97, 0.99), p<0.001 0.98 (0.97, 0.99), p<0.001 
Black or minority ethnic group 0.84 (0.49, 1.42), p=0.507 0.88 (0.58, 1.33), p=0.541 
Deprivation quintile b   
   2 1.19 (0.90, 1.57), p=0.229 1.64 (0.95, 2.81), p=0.074 
   3 0.69 (0.45, 1.07), p=0.100 1.68 (0.97, 2.92), p=0.063 
   4  0.73 (0.45, 1.20), p=0.215 1.37 (0.81, 2.33), p=0.245 
   5 (most deprived) 0.60 (0.28, 1.28), p=0.186 0.72 (0.35, 1.45), p=0.353 
Housing problems  1.79 (1.24, 2.59), p=0.002 1.43 (0.86, 2.36), p=0.164 
Paid employment  1.08 (0.83, 1.40), p=0.564 1.03 (0.69, 1.53), p=0.903 
Clinical a   
Days alcohol use  0.92 (0.89, 0.95), p<0.001 1.02 (0.98, 1.06), p=0.280 
DDD group: c   
Abstinent  3.30 (1.81, 6.03), p<0.001 1.27 (0.63, 2.54), p=0.506 
Low-High  0.82 (0.59, 1.15), p=0.253 0.89 (0.60, 1.32), p=0.568 
Extreme 0.91 (0.70, 1.19), p=0.505 1.16 (0.87, 1.55), p=0.325 
Previous treatment for AUD  0.78 (0.59, 1.04), p=0.088 1.26 (0.88, 1.80), p=0.209 
Referral route: d   
Self/family member/friend 1.66 (1.12, 2.48), p=0.012 1.22 (0.83, 1.80), p=0.309 
Criminal justice 1.33 (0.59, 2.96), p=0.490 2.05 (0.75, 5.65), p=0.164 
Treatment exposure    
Total weeks in treatment  1.01 (1.00, 1.02), p=0.023 1.04 (1.03, 1.05), p<0.001 
Prior structured community-based treatment  0.49 (0.28, 0.85), p=0.011 1.54 (0.87, 2.71), p=0.139 
Subsequent structured community-based treatment 0.15 (0.05, 0.43), p=0.001 0.10 (0.04, 0.25), p<.001 
Recovery support 0.68 (0.31, 1.47), p=0.324 2.47 (1.05, 5.81), p=0.038 
IW, inpatient withdrawal; RR, residential rehabilitation; IW + RR, inpatient withdrawal and residential rehabilitation; 
DDD, drinks per drinking day; AUD, alcohol use disorder. 
 
Numbers in table are relative risks (95% confidence intervals) and p-values.  
 
Referent group in multinomial model is: Inpatient (n=2,682) 
 
a  Recorded at triage assessment with reference to the preceding 28 days as appropriate; b Referent category: 
Deprivation first quartile; c Referent category: High-Extreme, recoded at treatment commencement with reference to 
the preceding 28 days were appropriate; d Referent category: Health service.
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Table 3 
Treatment status and outcome at 6-month follow-up (n=3,812) 
 
Status/outcome 
IW  
(n=2,682) 
RR  
(n=915) 
Combined  
(IW + RR; n=215) 
Total  
(n=3,812) 
Treatment status     
No. (%) successfully completed 1560 (58.2) 595 (65.0) 123 (57.2) 2278 (59.8) 
No. (%) unsuccessful agency transfer   504 (18.8) 97 (10.6) 34 (15.8) 635 (16.7) 
No. (%) still in treatment 207 (7.7) 47 (5.1) 29 (13.5) 283 (7.4) 
No. (%) dropped out 369 (13.8) 175 (19.1) 27 (12.6) 571 (15.0) 
No. (%) prison terminated treatment 1 (0) 0 (0) 0 (0) 1 (0) 
No. (%) died in treatment 41 (1.5) 1 (0.1) 2 (0.9) 44 (1.2) 
Outcome (excluding those still in treatment; n=3,529)     
No. (%) SCNR outcome 1417 (57.3) 554 (63.8) 105 (56.5) 2076 (58.8) 
SCNR, successful completion of treatment and no representation within 6 months; IW, inpatient withdrawal; RR, residential rehabilitation; IW + RR, inpatient withdrawal and 
residential rehabilitation
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Table 4 
Multi-level, mixed effects, multivariable logistic model of SCNR outcome for inpatient (n=2,475) and residential 
rehabilitation (n=1,054) samples  
 
Covariate 
IW 
(n=2,475) 
RR/Combined 
(n=1,054) 
Socio-demographic a   
Male 0.93 (0.77, 1.13), p=0.484 0.84 (0.62, 1.15), p=0.277 
Age 1.01 (1.01, 1.02), p=0.002 1.00 (0.99, 1.01), p=0.989 
Black or minority ethnic group 0.90 (0.67, 1.21), p=0.486 
 
1.51 (0.92, 2.49), p=0.103 
 
Deprivation quintile: b   
   2 1.11 (0.81, 1.51), p=0.512 1.16 (0.76, 1.78), p=0.491 
   3 0.99 (0.73, 1.34), p=0.929 1.02 (0.64, 1.64), p=0.928 
   4  0.96 (0.71, 1.30), p=0.785 0.78 (0.49, 1.24), p=0.293 
   5 (most deprived) 1.03 (0.76, 1.41), p=0.830 0.87 (0.54, 1.40), p=0.555 
Housing problems  0.67 (0.51, 0.88), p=0.004 0.95 (0.65, 1.37), p=0.771 
Paid employment  1.32 (1.03, 1.70), p=0.028 1.52 (1.02, 2.26), p=0.038 
Clinical a   
DDD group: c   
Abstinent  1.29 (0.78, 2.16), p=0.324 0.69 (0.42, 1.13), p=0.139 
Low-High  1.07 (0.82, 1.40), p=0.615 1.10 (0.69, 1.74), p=0.700 
Extreme 0.90 (0.73, 1.10), p=0.301 0.95 (0.67, 1.34), p=0.749 
Previous treatment for AUD 0.90 (0.75, 1.08), p=0.253 0.82 (0.61, 1.10), p=0.177 
Referral source: d   
   Self/family member/friend 1.22 (0.97, 1.54), p=0.090 1.89 (1.37, 2.60), p<0.001 
   Criminal justice 1.23 (0.52, 2.89), p=0.636 0.76 (0.26, 2.24), p=0.616 
Treatment exposure   
Days IW exposure  1.00 (1.00, 1.00), p=0.290 - 
Weeks RR exposure - 1.09 (1.07, 1.11), p<0.001 
Received IW - 0.60 (0.38, 0.94), p=0.026 
Any prescribing in RR - 1.18 (0.80, 1.73), p=0.405 
Prior structured community-based treatment  1.59 (1.17, 2.17), p=0.003 0.67 (0.45, 0.99), p=0.047 
Subsequent structured community-based treatment  1.47 (1.11, 1.96), p=0.008 1.69 (1.10, 2.60), p=0.016 
Recovery support 1.06 (0.82, 1.37), p=0.681 0.69 (0.48, 1.00), p=0.047 
Model parameters   
Treatment clinic (ICC) e 0.17, 0.18 0.09, 0.10 
Constant 0.41 (0.23, 0.74) 0.76 (0.32, 1.78) 
Wald e 104.34, 106.42 99.61, 104.26 
LR e 171.69, 176.13 13.38, 15.33 
SCNR, successful completion of treatment and no representation within 6 months; IW, inpatient withdrawal; RR, 
residential rehabilitation; IW + RR, inpatient withdrawal and residential rehabilitation; DDD, drinks per drinking day; 
AUD, alcohol use disorder; ICC, intra-class correlation; LR, Likelihood-Ratio Test. 
 
Numbers in table are adjusted odds ratios (95% confidence intervals) with p-values. These outputs are based on 
multiple imputation.  
 
a  Recorded at triage assessment with reference to the preceding 28 days as appropriate; b Referent category: 
Deprivation first quartile; c Referent category: High-Extreme, recoded at treatment commencement with reference to 
the preceding 28 days were appropriate; d Referent category: Health service; e Range for imputed models reported here
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Table S1 
Multi-level, mixed effects, multivariable logistic model SCNR outcome for inpatient (n=2,324) 
and residential rehabilitation (n=963) samples (complete-case analysis) 
 
Covariate 
IW 
(n=2,324) 
RR/Combined  
(n=963) 
Socio-demographic a   
Male 0.89 (0.73, 1.09), p=0.274 0.88 (0.64, 1.21), p=0.444 
Age 1.01 (1.00, 1.02), p=0.007 1.00 (0.98, 1.01), p=0.611 
Black or minority ethnic group  0.93 (0.69, 1.25), p=0.632 1.56 (0.92, 2.64), p=0.097 
Deprivation quintile: b   
   2 1.13 (0.82, 1.55), p=0.464 1.20 (0.77, 1.88), p=0.414 
   3 0.99 (0.73, 1.35), p=0.952 1.13 (0.69, 1.85), p=0.618 
   4  0.92 (0.68, 1.26), p=0.619 0.84 (0.52, 1.36), p=0.474 
   5 (most deprived) 1.03 (0.75, 1.42), p=0.850 0.83 (0.50, 1.38), p=0.463 
Housing problems  0.65 (0.49, 0.85), p=0.002 0.94 (0.64, 1.39), p=0.757 
Paid employment  1.29 (1.00, 1.67), p=0.048 1.62 (1.07, 2.46), p=0.023 
Clinical a   
DDD group: c   
Abstinent  1.27 (0.75, 2.14), p=0.370 0.63 (0.37, 1.06), p=0.079 
Low-Extreme  1.09 (0.83, 1.44), p=0.519 1.13 (0.70, 1.82), p=0.624 
Extreme 0.87 (0.70, 1.08), p=0.198 0.88 (0.61, 1.26), p=0.489 
Previous treatment for AUD 0.89 (0.74, 1.08), p=0.243 0.82 (0.60, 1.12), p=0.221 
Referral source: d   
   Self/family member/friend 1.18 (0.93, 1.50), p=0.162 1.97 (1.40, 2.76), p<0.001 
   Criminal justice 1.22 (0.52, 2.87), p=0.645 0.71 (0.23, 2.19), p=0.548 
Treatment exposure   
Days IW exposure  1.00 (1.00, 1.00), p=0.239 - 
Weeks RR exposure - 1.09 (1.07, 1.11), p<0.001 
Received IW - 0.54 (0.34, 0.85), p=0.009 
Any prescribing in RR - 1.08 (0.72, 1.60), p=0.719 
Prior community-based treatment  1.49 (1.09, 2.06), p=0.013 0.59 (0.39, 0.89), p=0.012 
Subsequent community-based treatment  1.38 (1.03, 1.84), p=0.030 1.64 (1.06, 2.56), p=0.028 
Recovery support 1.02 (0.79, 1.33), p=0.862 0.77 (0.52, 1.13), p=0.181 
Model parameters   
Treatment clinic (ICC)  0.17 0.08 
Constant 0.55 (0.30, 0.99) 0.87 (0.36, 2.15) 
Wald  82.33 102.97 
LR  142.31 10.01 
IW, inpatient withdrawal; RR, residential rehabilitation; IW + RR, inpatient withdrawal and 
residential rehabilitation; DDD, drinks per drinking day; AUD, alcohol use disorder; ICC, intra-class 
correlation; LR, Likelihood-Ratio Test. 
 
Numbers in table are adjusted odds ratios (95% confidence intervals) and p-values. These outputs are 
based on complete-case analysis.  
 
a  Recorded at triage assessment with reference to the preceding 28 days as appropriate; b Referent 
category: Deprivation first quartile; c Referent category: High-Extreme, recoded at treatment 
commencement with reference to the preceding 28 days were appropriate;  d Referent category: Health 
service.  
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